EPZM Epizyme Inc.

14.86
-0.33  -2%
Previous Close 15.18
Open 15.09
Price To Book 5.29
Market Cap 1,352,903,408
Shares 91,073,942
Volume 515,305
Short Ratio
Av. Daily Volume 714,094
Stock charts supplied by TradingView

NewsSee all news

  1. Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme

    NEW YORK, Nov. 5, 2019 /PRNewswire/ -- Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.'s royalties on future worldwide sales of tazemetostat, Epizyme Inc.'s

  2. Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement

    $100 Million Upfront Investment by Royalty Pharma with Up to $100 Million in Future Equity Existing Royalty Obligation on Future Tazemetostat Sales Reduced with Royalty Pharma $70 Million Expandable Loan Facility

  3. Epizyme Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results

    Pre-NDA Meeting Supports Registration Strategy for Tazemetostat for Follicular Lymphoma Patients with and without EZH2 Activating Mutations and Planned NDA Submission in December 2019 Updated Phase 2 Follicular

  4. Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointments of experienced commercial executive, Grant Bogle, and research and development

  5. Epizyme to Participate in Upcoming September Conferences

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in the following

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 dosing commenced August 2016. Noted April 23, 2018 that all Tazemetostat trials have been placed on partial clinical hold.
Tazemetostat
Adult patients with mesothelioma characterized by BAP1 loss-of-function
NDA filing due December 2019. Updated Phase 2 data due at ASH 2019.
Tazemetostat
Follicular lymphoma
PDUFA date priority review January 23, 2020.
Tazemetostat
Epithelioid Sarcoma
Phase 1b enrollment complete.
Tazemetostat + Atezolizumab
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Latest News

  1. Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme

    NEW YORK, Nov. 5, 2019 /PRNewswire/ -- Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.'s royalties on future worldwide sales of tazemetostat, Epizyme Inc.'s

  2. Epizyme Establishes Agreements for Up to $270 Million in Funding to Support Tazemetostat Commercialization and Pipeline Advancement

    $100 Million Upfront Investment by Royalty Pharma with Up to $100 Million in Future Equity Existing Royalty Obligation on Future Tazemetostat Sales Reduced with Royalty Pharma $70 Million Expandable Loan Facility

  3. Epizyme Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results

    Pre-NDA Meeting Supports Registration Strategy for Tazemetostat for Follicular Lymphoma Patients with and without EZH2 Activating Mutations and Planned NDA Submission in December 2019 Updated Phase 2 Follicular

  4. Epizyme Announces Board of Director Appointments to Support Continued Evolution and Growth

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced the appointments of experienced commercial executive, Grant Bogle, and research and development

  5. Epizyme to Participate in Upcoming September Conferences

    Epizyme, Inc. (NASDAQ:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in the following